Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.
about
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseAdvances in development of fluorescent probes for detecting amyloid-β aggregatesCurrent Research Therapeutic Strategies for Alzheimer's Disease TreatmentFirst-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.Drug candidates in clinical trials for Alzheimer's disease.High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide.A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio.The nuclear retention of transcription factor FOXO3a correlates with a DNA damage response and increased glutamine synthetase expression by astrocytes suggesting a neuroprotective role in the ageing brain.Discovery of a novel fluorescent probe for the sensitive detection of β-amyloid deposits.A novel recombinant 6Aβ15-THc-C chimeric vaccine (rCV02) mitigates Alzheimer's disease-like pathology, cognitive decline and synaptic loss in aged 3 × Tg-AD mice.Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine.Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians.Dantrolene, a treatment for Alzheimer disease?Benefits and risks of add-on therapies for Alzheimer's disease.Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.Alzheimer's disease and immunotherapy: what is wrong with clinical trials?Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation.Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic miceLong-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer's Disease.Autophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice.Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target.Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease.The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.Focal molography is a new method for the in situ analysis of molecular interactions in biological samples.Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease.Emerging amyloid disease-modifying drugs for Alzheimer's disease.
P2860
Q26739412-C244B013-F502-4BEC-AF0B-6FA585C51E27Q26753175-16AC2BE5-CF83-4562-B9FB-6688AF29D5A1Q26765530-C2BEF171-CDBB-4C5F-8212-973779E2EC5CQ31050126-C5919024-7B39-43B6-B56D-52A5DFC0647CQ33916749-24AA8148-5E13-43D7-B6DF-D1FFAADC51CDQ35974386-00BC2AAA-458D-4FEB-859C-828DC7A0CB3AQ36240389-C8431C85-F7EB-4547-9185-8652A9BCD128Q36267484-850E47D7-2B47-46A3-9583-8508B4617B02Q36360986-789088AD-F685-4093-95FA-21C2D8AF8E52Q36920551-B4BCB99A-50B4-4029-AC92-A9EAA68544A0Q36964826-2674E6A2-8BAD-4816-8CD6-8A85A489885EQ37473219-1DC12866-C509-4758-80B0-46C7212727EBQ38224958-14AE0E79-6C3D-4B91-8544-99840AD07C6EQ38235780-3D2D66C2-5A2F-43DB-8F91-4CA8E0D23A31Q38269095-6D561C7C-3596-4206-B3F7-67B25B08C620Q38304771-F3906A50-5D5C-43E1-BA3F-EC7E41FCA863Q38620338-21DA242F-F0C7-4951-A467-C194A84308E9Q38719665-629F094A-C4AD-441D-8E5E-D84E35F5F922Q38802634-6F3AFD2D-7879-4A6E-A6D1-B6ECA1C60757Q38912275-A0CCA478-97C7-4E20-950F-7D208B102DF5Q38928927-86F252B1-7F3D-4DEB-8A42-35637A91C6C9Q38966308-AF6141E3-1E30-4B7B-B6B1-4FA4B6B23F75Q39775642-3DAA757D-71F8-4ABA-A79A-6C4AC9A6ECA9Q41248630-2E9618B3-EB14-4F61-AC83-48AAC6560BA5Q41465460-8EC0C6C1-5EB1-4334-9603-D712311D6CEEQ42007256-AD9BFFA1-783A-4197-927E-3DEB53308D28Q45300233-EC919866-3DEB-4800-8F87-F3C4C559D6D6Q47567135-9C5A98C2-FE09-44BA-9FA6-7C2E16C085D7Q47637110-B490A18E-BA78-479B-8461-28B9717223C8Q48445250-D77C4181-D76C-493C-9708-028A2C173EBDQ53372767-B745F11C-30C2-42E2-836E-E25D74E5CF1E
P2860
Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Amyloid-based immunotherapy fo ...... ntion trials: the way forward.
@en
type
label
Amyloid-based immunotherapy fo ...... ntion trials: the way forward.
@en
prefLabel
Amyloid-based immunotherapy fo ...... ntion trials: the way forward.
@en
P2093
P2860
P1476
Amyloid-based immunotherapy fo ...... ntion trials: the way forward.
@en
P2093
Andrea Santamato
Bruno P Imbimbo
Rosanna Tortelli
Vincenzo Solfrizzi
P2860
P304
P356
10.1586/1744666X.2014.883921
P577
2014-02-04T00:00:00Z